Custom Search

News

Thursday 01 September 2005

Regression of pulmonary MALT lymphoma after treatment with rituximab.

By: Chong EA, Svoboda J, Cherian S, Andreadis C, Downs LH, Zhuang H, Alavi A, Tsai DE, Schuster SJ.

Leuk Lymphoma 2005 Sep;46(9):1383-6

We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 months after finishing her treatment. This case report demonstrates the potential efficacy of rituximab as a single therapeutic agent in patients with pulmonary MALT lymphoma.

Use of this site is subject to the following terms of use